Who owns PUMA BIOTECHNOLOGY, INC. (PBY)? Elite investor 13F holders
2 tracked elite investors reported holding PUMA BIOTECHNOLOGY, INC as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | PUMA BIOTECHNOLOGY INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 14891687.00 USD | 1836213.000000 | Shares | reduce | Original filing |
| D.E. Shaw | PUMA BIOTECHNOLOGY INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2565542.00 USD | 316343.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.